BMEA (biomeafusion.com) Market Value to Book Value Ratio

Official company branding of Biomea Fusion Inc (BMEA)

Biomea Fusion, Inc. (BMEA) develops covalent molecules to combat cancer and diabetes, diversifying risks across various therapeutic areas. This asset price chart highlights the flexibility of a model where production and testing are outsourced to third-party contractors. The current metric stands at 3.76. The ultimate outcome of development depends on the results of menin inhibitor trials, which necessitates safety monitoring supported by sufficient liquidity.

BMEA Biomea Fusion Corp: Market Value to Book Value in the range 07/04/2022 - 10/28/2026

Financial and market metric breakdowns for Biomea Fusion Inc (BMEA)

- price and consensus price forecast:
Stock Price Biomea Fusion, Inc.|BMEA - Analyst Consensus Forecast
- market capitalization data:
Market Value Biomea|BMEA - Full Business Value
- book capitalization data:
Book Value per Share Biomea Fusion|BMEA - Accounting Value of Company|Market Capitalization to Book Value Ratio biomeafusion.com|BMEA - Company Total Assets
- debt and liquidity data:
Debt to Equity Biomea Fusion, Inc.|BMEA - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Biomea|BMEA - Company Total Debt|Debts to Book Capitalization Biomea|BMEA - Company Long-Term Debts|Company Current Liabilities Biomea Fusion
Initial company analysis:Biomea Fusion, Inc. - BMEA
Original product of Biomea

This ratio reflects the premium of the company's market value over its net equity, allowing for an assessment of whether assets are overvalued or undervalued. Analyzing the market cap to book value ratio for Biomea Fusion, Inc. (BMEA) is critically important, as the value of intellectual property regarding beta-cell restoration in the biotechnology sector often significantly exceeds the tangible resources recorded on the balance sheet.

Main competitors

ASND: Market Capitalization to Book Value Ratio|MDGL (madrigalpharma.com) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Corcept Therapeutics Incorporated CORT|Market Capitalization to Net Assets Rhythm Pharma|Akero Therapeutics Inc (AKRO) - Market Capitalization to Book Value Ratio|Market Value to Book Value Metsera Therapeutics (MTSR)|Market Capitalization to Book Value Ratio MLTX (MoonLake Immunotherapeutics)|crinetics.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio NewAmsterdam Pharma Company N.V. (NAMS)|SLNO: Market Value to Book Value|FOLD (Amicus Pharma) - Market Value to Book Value Ratio|89bio Pharma (ETNB) - Market Cap to Net Assets Ratio|AGIO (Agios Pharmaceuticals) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio structuretx.com (GPCR)|MiMedx (MDXG) - Market Cap to Net Assets Ratio|Market Value to Book Value RZLT (Rezolute Inc)|Lexicon Pharma - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio MBX Corp MBX|ALT (Altimmune, Inc.) - Market Capitalization to Book Value Ratio|aardvarktherapeutics.com (AARD) - Market-to-Book Ratio|SGMT - Market Cap to Net Assets Ratio|BioAge Labs (BIOA) - Market Cap to Book Value Multiple|QNCX (Quince Therapeutics Inc) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Fractyl Health, Inc|Market Capitalization to Book Value Ratio vTv Therapeutics Inc. (VTVT)|Market Value to Book Value Ratio ATPC (agapeatpgroup.com)|PLUR: Market Value to Book Value Ratio|Synlogic Inc. - Market-to-Book Ratio|LPCN - Market Value to Book Value Ratio|MTNB - Market Value to Book Value Ratio|Spruce Biosciences - Market Capitalization to Book Value Ratio|GLTO (galecto.com) - Market Capitalization to Book Value|CTCX: Market Value to Book Value Ratio|Market Capitalization to Book Value LUMO|Market Value to Book Value Ratio ONVO (Organovo Holdings Inc)|Market Cap to Net Assets Ratio Radius Pharmaceuticals (RDUS)